# Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects

Study · id `cardio:ct-nct03141073` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03141073](<https://clinicaltrials.gov/study/NCT03141073>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03141073

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 767 participants.

## Technical summary

Registry record NCT03141073. Randomized; quadruple masking; primary purpose treatment. Start 2017-10-15 (actual); primary completion 2021-02-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 767 participants (enrolled count; ClinicalTrials.gov record NCT03141073, source copy `cardio:ctgov-nct03141073-2021-08-26`, retrieved 2026-10-26)
- Started: 2017-10-15 (actual) (ClinicalTrials.gov record NCT03141073, source copy `cardio:ctgov-nct03141073-2021-08-26`, retrieved 2026-10-26)
- Primary completion: 2021-02-28 (actual) (ClinicalTrials.gov record NCT03141073, source copy `cardio:ctgov-nct03141073-2021-08-26`, retrieved 2026-10-26)
- Completion: 2021-02-28 (actual) (ClinicalTrials.gov record NCT03141073, source copy `cardio:ctgov-nct03141073-2021-08-26`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03141073, source copy `cardio:ctgov-nct03141073-2021-08-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03141073-2021-08-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Long-term Efficacy and Safety of HMS5552 add-on to Metformin in T2DM Subjects
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): HMS5552
- Intervention (Drug): Placebo
- Lead sponsor: Hua Medicine Limited
- Lead sponsor class: INDUSTRY
- Collaborator: Covance
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Hua Medicine Limited (`cardio:org-hua-medicine-limited`)
- Registry lists this organization as a collaborator: Covance (`cardio:org-covance`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial (`cardio:pubmed-35551292`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 457c19dec539597e3d66a14b5a2833a39ec47738efcadb9d02f40b329f1a0f61
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
